Overview The Clostridioides Difficile Trial of REC-3964 Status: TERMINATED Trial end date: 2025-05-06 Target enrollment: Participant gender: Summary This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of RE-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).Phase: PHASE2 Details Lead Sponsor: Recursion Pharmaceuticals Inc.